Prostate microenvironment and prostate cancer progression - Chromosomal damage and genomic instability are hallmarks of carcinogenesis, and micronutrients and genetics interact to protect the genome against this deleterious process. Recent evidence from our group and others suggests that several antioxidant nutrients may protect against the development of prostate cancer, and genetic variants involved with DNA repair and antioxidant metabolism may modify the influence of pre-diagnostic antioxidant status on prostate cancer risk. Through the following 3 Specific Aims, we will expand on these findings and investigate whether circulating post-diagnostic antioxidants (i.e. lycopene, total carotenoids, alpha- & gamma- tocopherol, and selenium) and genotypes (i.e. MnSOD, GPX1, GSTM1, GSTT1, XRCC1, OGG1) are associated with:
(Aim 1) prostate cancer clinical phenotype:
(Aim 2) prostate tumor genomic instability:
and (Aim 3) risk of recurrence/ progression. Gleason score at diagnosis (biopsy) will reflect clinical phenotype; and global tumor copy number aberrations will indicate tumor gerbmic instability. We will evaluate 1000 men from an existing study who were diagnosed with incident localized/regional prostate cancer, donated blood and tissue for research purposes prior to treatment, and consented to follow-up. We hypothesize that lower circulating lycopene, total carotenoids, alpha- & gamma-tocopherol, and selenium and specific gene variants will be associated with increased Gleason score, tumor genomic instability, and risk of recurrence/progression. We also hypothesize that these circulating antioxidants and genetic variants will interact to affect the aggressiveness and course of disease. The goal of this project is to determine whether antioxidant nutrition after cancer initiation influences tumor aggressiveness and progression, and whether this depends on genotype. Strengths of this study include the 1) scientific novelty and importance, 2) efficiency of building on existing studies, 3) clinical and public health relevance, 4) multi-disciplinary collaborative research team, and 5) excellent resources of UGSF and DFCI. This study may lead to improved public health through the development of new nutritional guidelines for cancer patients, or the initiation of adjuvant or neoadjuvant randomized clinical trials of antioxidant interventions, focused on populations with specific genotypes. ? ?

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Project (R01)
Project #
5R01CA106947-03
Application #
7485604
Study Section
Epidemiology of Cancer Study Section (EPIC)
Program Officer
Reid, Britt C
Project Start
2006-09-01
Project End
2010-08-31
Budget Start
2008-09-01
Budget End
2009-08-31
Support Year
3
Fiscal Year
2008
Total Cost
$183,391
Indirect Cost
Name
University of California San Francisco
Department
Public Health & Prev Medicine
Type
Schools of Medicine
DUNS #
094878337
City
San Francisco
State
CA
Country
United States
Zip Code
94143
Peisch, Sam F; Van Blarigan, Erin L; Chan, June M et al. (2017) Prostate cancer progression and mortality: a review of diet and lifestyle factors. World J Urol 35:867-874
Nordström, Tobias; Van Blarigan, Erin L; Ngo, Vy et al. (2016) Associations between circulating carotenoids, genomic instability and the risk of high-grade prostate cancer. Prostate 76:339-48
Chan, June M; Darke, Amy K; Penney, Kathryn L et al. (2016) Selenium- or Vitamin E-Related Gene Variants, Interaction with Supplementation, and Risk of High-Grade Prostate Cancer in SELECT. Cancer Epidemiol Biomarkers Prev 25:1050-1058
Xie, Wanling; Yang, Ming; Chan, June et al. (2016) Association of genetic variations of selenoprotein genes, plasma selenium levels, and prostate cancer aggressiveness at diagnosis. Prostate 76:691-9
Gerstenberger, John P; Bauer, Scott R; Van Blarigan, Erin L et al. (2015) Selenoprotein and antioxidant genes and the risk of high-grade prostate cancer and prostate cancer recurrence. Prostate 75:60-9
Margalit, Danielle N; Jordahl, Kristina M; Werner, Lillian et al. (2015) GermLine Variation in Superoxide Dismutase-2 (SOD2) and Survival Outcomes After Radiation Therapy for Prostate Cancer: Results of a Test and Validation Set Analysis. Clin Genitourin Cancer 13:370-377.e1
Chan, June M; Van Blarigan, Erin L; Kenfield, Stacey A (2014) What should we tell prostate cancer patients about (secondary) prevention? Curr Opin Urol 24:318-23
Van Blarigan, Erin L; Ma, Jing; Kenfield, Stacey A et al. (2014) Plasma antioxidants, genetic variation in SOD2, CAT, GPX1, GPX4, and prostate cancer survival. Cancer Epidemiol Biomarkers Prev 23:1037-46
Bauer, Scott R; Richman, Erin L; Sosa, Eduardo et al. (2013) Antioxidant and vitamin E transport genes and risk of high-grade prostate cancer and prostate cancer recurrence. Prostate 73:1786-95
Dhillon, Preet K; Kenfield, Stacey A; Stampfer, Meir J et al. (2012) Aspirin use after a prostate cancer diagnosis and cancer survival in a prospective cohort. Cancer Prev Res (Phila) 5:1223-8

Showing the most recent 10 out of 12 publications